2299252-72-3
Chemical Structure
Izumerogant
Synonym(s): IMU-935
- CAS No.: 2299252-72-3
- Formula:C22H18ClF4N5O2
- Molecular Weight:495.86
IUPAC Name: ((1S,2R,5S)-2-(((5-fluoropyridin-2-yl)oxy)methyl)-8-azabicyclo[3.2.1]octan-8-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone
InChIKey: MRJLIFZIFUEXQG-UHFFFAOYSA-N
SMILES: FC1=CC=CC(Cl)=C1C2=NOC(C3=C(C(F)(F)F)N(CCC(C)(C)O)N=C3)=C2C4=NC=CC=N4
Biological Activity: Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Izumerogant | 99.95% | Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RORγ/DHODH-IN-2 | RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. F Jakob, et al. Isoxazole-pyrazole derivatives and related compounds as IL-17 and IFN-γ inhibitors for treating autoimmune diseases and chronic inflammation: World Intellectual Property Organization, WO2019048541. 2019-03-14.
- [2]. Polasek TM, et al. Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2023 May;12(5):525-534. [Content Brief]
Keywords
